Full Year
RZLT — FY2026 Annual Financial Report Analysis
Rezolute's FY2026 net loss widened to $77.6M as R&D fell and pre-launch G&A rose 59%. Cash and investments fell to $107.8M after the sunRIZE Phase 3 miss, with upLIFT tumor-HI topline data due by end-2026.